Why the study?
What is the incidence of antibodies to double-stranded RNA in patients with SLE compared to normal controls and other diseases?
What is the incidence of antibodies to double-stranded RNA in patients with SLE compared to normal controls and other diseases?
Antibodies to double-stranded RNA are highly prevalent in SLE compared to normal controls and other autoimmune diseases, potentially indicating a response to viral infection.
Answers are grounded in this paper and cite their sources.
Anti-dsRNA antibodies in SLE should not yet change diagnostics; cross-sectional data leave open viral etiology for prospective study.
Sera from patients with systemic lupus erythematosus (SLE) and related diseases were examined for antibodies to double‐stranded RNA (DSRNA) by precipitation, complement fixation and radioactive antigen binding. While only 6% of normals had antibodies to DSRNA, 51% of patients with SLE had these antibodies. A low incidence of these antibodies was seen in patients with progressive systemic sclerosis, juvenile rheumatoid arthritis, myasthenia gravis, thyroiditis, multiple myeloma, rheumatoid arthritis, Sjögren's syndrome, drug‐induced SLE and various forms of liver disease. These antibodies reacted to synthetic and naturally occurring DSRNA, but not to single‐stranded RNA or DNA. As DSRNA is found in cells primarily during viral replication, these antibodies may represent a response to viral infection.
No takes yet. Share an insight, caveat, or question.
Schur et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: